Literature DB >> 22263027

The role of survivin in diagnosis, prognosis and treatment of breast cancer.

Yong-Gang Lv1, Fang Yu, Qing Yao, Jiang-Hao Chen, Ling Wang.   

Abstract

Survivin is a cancer gene that is silenced in differentiated tissues, while overexpressed at high levels in vast majority of tumors. It has garnered great interests in recent years. Some essential properties characterizing it as an ideal target involve inhibiting apoptosis, promoting mitosis, stimulating vessel growth thus inducing chemo-resistance. These functions touch the full gamut of tumorigenesis, including proliferation, migration, and invasion, and collectively facilitate malignant behavior. In the case of breast cancer, survivin detection independent or combined in serum and/or urine has emerged as a measure for diagnosis. Moreover, many studies indicated aberrant expression of survivin is associated with poor prognosis and drug/radiation resistance. Strategies targeting survivin to treat breast cancer have got promising initial results. In this review, we summarize its role in breast cancer's diagnosis, prognosis, and treatment, with the intention to explain why this interesting molecule plays a conflicting role.

Entities:  

Keywords:  breast neoplasm; diagnosis; prognosis; survivin; treatment

Year:  2010        PMID: 22263027      PMCID: PMC3256445     

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  132 in total

Review 1.  Survivin study: what is the next wave?

Authors:  Fengzhi Li
Journal:  J Cell Physiol       Date:  2003-10       Impact factor: 6.384

2.  Do the survivin (BIRC5) splice variants modulate or add to the prognostic value of total survivin in breast cancer?

Authors:  Paul N Span; Vivianne C G Tjan-Heijnen; Joop J T M Heuvel; Jacques B de Kok; John A Foekens; Fred C G J Sweep
Journal:  Clin Chem       Date:  2006-07-27       Impact factor: 8.327

3.  Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin.

Authors:  D S O'Connor; D Grossman; J Plescia; F Li; H Zhang; A Villa; S Tognin; P C Marchisio; D C Altieri
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-21       Impact factor: 11.205

4.  Solution structure of human survivin and its binding interface with Smac/Diablo.

Authors:  Chaohong Sun; David Nettesheim; Zhihong Liu; Edward T Olejniczak
Journal:  Biochemistry       Date:  2005-01-11       Impact factor: 3.162

5.  Down-regulation of survivin expression reversed multidrug resistance in adriamycin-resistant HL-60/ADR cell line.

Authors:  Lei Wang; Gui-Mei Zhang; Zuo-Hua Feng
Journal:  Acta Pharmacol Sin       Date:  2003-12       Impact factor: 6.150

Review 6.  Targeting survivin in cancer therapy.

Authors:  Marzia Pennati; Marco Folini; Nadia Zaffaroni
Journal:  Expert Opin Ther Targets       Date:  2008-04       Impact factor: 6.902

7.  [Application of suspension array assay to detect marker genes expression of circulating tumor cells for early prediction of breast cancer metastasis].

Authors:  Feng Ke; Jian-Min Wu; Jian-Er Yao; Yan-Jun Bai; An-Liang Guo
Journal:  Zhonghua Yi Xue Za Zhi       Date:  2007-08-28

8.  Real-time quantification of CK-19 mRNA-positive cells in peripheral blood of breast cancer patients using the lightcycler system.

Authors:  Aliki Stathopoulou; Anna Gizi; Maria Perraki; Stella Apostolaki; Nikos Malamos; Dimitris Mavroudis; Vassilis Georgoulias; Evi S Lianidou
Journal:  Clin Cancer Res       Date:  2003-11-01       Impact factor: 12.531

9.  A p34(cdc2) survival checkpoint in cancer.

Authors:  Daniel S O'Connor; Nathan R Wall; Andrew C G Porter; Dario C Altieri
Journal:  Cancer Cell       Date:  2002-07       Impact factor: 31.743

10.  Nuclear survivin has reduced stability and is not cytoprotective.

Authors:  Claire M Connell; Rita Colnaghi; Sally P Wheatley
Journal:  J Biol Chem       Date:  2007-12-05       Impact factor: 5.157

View more
  29 in total

1.  Systemic treatment with capecitabine as maintenance therapy in patients with recurring or metastatic breast cancer: experience in the Oncology Hospital, National Medical Center Siglo XXI, Mexican Social Security Institute.

Authors:  Manuel Segura-González; Miguel Quintana-Quintana
Journal:  Med Oncol       Date:  2015-02-27       Impact factor: 3.064

2.  Prostate cancer cells hyper-activate CXCR6 signaling by cleaving CXCL16 to overcome effect of docetaxel.

Authors:  Neeraj Kapur; Hina Mir; Guru P Sonpavde; Sanjay Jain; Sejong Bae; James W Lillard; Shailesh Singh
Journal:  Cancer Lett       Date:  2019-04-08       Impact factor: 8.679

3.  Breast cancer cells respond differently to docetaxel depending on their phenotype and on survivin upregulation.

Authors:  Francesca De Iuliis; Gerardo Salerno; Anna Giuffrida; Bernardina Milana; Ludovica Taglieri; Giovanna Rubinacci; Sabrina Giantulli; Federica Terella; Ida Silvestri; Susanna Scarpa
Journal:  Tumour Biol       Date:  2015-09-21

4.  The significance of expression of autophagy-related gene Beclin, Bcl-2, and Bax in breast cancer tissues.

Authors:  Qing Yao; Jianghao Chen; Yonggang Lv; Ting Wang; Juliang Zhang; Jing Fan; Ling Wang
Journal:  Tumour Biol       Date:  2011-08-23

5.  Expression of Y-Box-binding protein 1 in Chinese patients with breast cancer.

Authors:  Wenxiu Xie; Junlan Yang; Yuean Cao; Chaosheng Peng; Haoyong Ning; Fan Zhang; Junhao You
Journal:  Tumour Biol       Date:  2011-10-04

6.  Effects of ARHI on cell cycle progression and apoptosis levels of breast cancer cells.

Authors:  Ying Li; Li Shi; Chun Han; Yishang Wang; Junlan Yang; Cheng Cao; Shunchang Jiao
Journal:  Tumour Biol       Date:  2012-04-14

7.  Antitumor effect of the mTOR inhibitor everolimus in combination with trastuzumab on human breast cancer stem cells in vitro and in vivo.

Authors:  Yuanxi Zhu; Xiaobei Zhang; Yan Liu; Sheng Zhang; Jingjing Liu; Yi Ma; Jin Zhang
Journal:  Tumour Biol       Date:  2012-04-11

8.  Dysregulated expression of dicer and drosha in breast cancer.

Authors:  Min Yan; Hong-Yan Huang; Ting Wang; Yi Wan; Shu-De Cui; Zhen-Zhen Liu; Qing-Xia Fan
Journal:  Pathol Oncol Res       Date:  2011-09-07       Impact factor: 3.201

9.  The kinesin Eg5 inhibitor K858 induces apoptosis but also survivin-related chemoresistance in breast cancer cells.

Authors:  Francesca De Iuliis; Ludovica Taglieri; Gerardo Salerno; Anna Giuffrida; Bernardina Milana; Sabrina Giantulli; Simone Carradori; Ida Silvestri; Susanna Scarpa
Journal:  Invest New Drugs       Date:  2016-03-19       Impact factor: 3.850

10.  Sequestering survivin to functionalized nanoparticles: a strategy to enhance apoptosis in cancer cells.

Authors:  Ragini Jenkins; Yuriy P Bandera; Michael A Daniele; LeAnna L Ledford; Ashlee Tietje; Andrew A Kelso; Michael G Sehorn; Yanzhang Wei; Mrinmay Chakrabarti; Swapan K Ray; Stephen H Foulger
Journal:  Biomater Sci       Date:  2016-02-04       Impact factor: 6.843

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.